Azenta, Inc.
A life sciences company that helps researchers around the world store, manage, and analyze biological samples. Its automated ultra-cold freezers, sample tubes and vials, lab software, and cold-chain logistics keep everything from clinical-trial specimens to blood samples safe, while its GENEWIZ brand provides gene sequencing and DNA synthesis services. Founded in 1978 in Massachusetts as Brooks Automation, it spent decades building robots for making semiconductors before pivoting to biological samples and renaming itself Azenta in late 2021. Fittingly, the same robotics know-how that once handled delicate silicon wafers now gently shuffles frozen vials in automated freezers—an unexpected turn from chips to cells.
Bought 12.6K
Granted 10.7K
Granted 592.6K
Granted 599.7K
Granted 2.06M · Sold 930.4K
Granted 645.1K
Granted 223.6K
Granted 210.5K · Bought 15.0K · Sold 316
Granted 42.5K
Granted 188.0K · Sold 10.2K
Granted 135.0K
Granted 329.6K · Sold 141.0K
Granted 589.7K · Bought 24.4K · Sold 413.8K
Granted 65.0K · Sold 7.4K
Granted 411.9K · Sold 215.2K
Granted 99.5K
Granted 103.1K · Bought 2.3K
Granted 100.0K · Sold 17.1K
Granted 327.2K · Sold 268.5K
Granted 82.0K
Granted 143.7K · Sold 52.2K
Granted 89.2K · Bought 45.0K
Granted 104.1K · Sold 14.4K
Granted 80.0K
Granted 73.7K
Granted 75.0K
Granted 322.6K · Sold 185.9K
Granted 23.0K · Sold 3.4K
Granted 81.3K · Sold 7.5K
Granted 72.0K
Granted 80.0K · Sold 10.0K
Granted 51.8K · Sold 51.8K
Granted 44.1K · Bought 5.0K
Granted 172.7K · Sold 242.1K
Bought 29.5K
Granted 78.7K
Granted 37.1K · Bought 417 · Sold 1.6K
Granted 79.5K · Sold 36.1K
Granted 30.0K · Sold 7.0K
Granted 15.0K · Sold 40.1K
Granted 36.6K
Granted 10.0K
Granted 36.6K · Sold 3.0K
Granted 36.2K · Sold 1.6K
Granted 66.5K · Sold 21.9K
Bought 8.6K
Granted 165.4K · Sold 157.4K
Granted 18.2K · Sold 348
Granted 26.2K · Sold 2.3K
Granted 22.5K
Granted 21.8K
Sold 11.6K
Granted 206.2K · Sold 161.8K
Granted 17.8K
Granted 4.0K · Bought 12.0K
Granted 15.8K
Sold 5.0K
Granted 17.6K · Sold 4.6K
Granted 15.1K · Sold 2.3K
Granted 9.7K
Granted 8.6K · Sold 480
Granted 20.0K · Sold 10.5K
Granted 2.5K · Bought 4.9K
Granted 4.0K · Sold 132
Granted 7.2K
Granted 3.2K
Granted 3.6K
Granted 2.5K · Bought 1.0K
Granted 1.6K · Sold 191
Granted 2.5K
Granted 1.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Nierenberg Investment Management Co +2 co-filers10% owner · 4 transactions | — | 6.13Mas of Jul 2008 | — | 12.6K | — |
| Koffey QuentinDirector · 3 transactions | — | 4.62M | 10.7K | — | — |
| Lepofsky RobertChief Executive Officer, Director · 8 transactions | — | 884.2Kas of Oct 2010 | 592.6K | — | — |
| Headley Martin SEVP & Chief Financial Officer · 21 transactions | — | 506.7Kas of Feb 2013 | 599.7K | — | — |
| Schwartz Stephen SCEO, Director · 101 transactions | — | 446.5Kas of Nov 2023 | 2.06M | — | 930.4K |
| Morelli Mark DPresident and COO · 16 transactions | — | 414.9Kas of Nov 2015 | 645.1K | — | — |
| Steven A. MichaudSVP, Brooks Product Solutions · 22 transactions | — | 223.3Kas of Nov 2012 | 223.6K | — | — |
| Marotta JohnPresident and CEO, Director · 10 transactions | — | 213.2K | 210.5K | 15.0K | 316 |
| Schorr Marvin GDirector · 6 transactions | — | 158.8Kas of Feb 2011 | 42.5K | — | — |
| Haris Clinton M.SVP, Brooks Life Sciences · 34 transactions | — | 151.4Kas of Nov 2013 | 188.0K | — | 10.2K |
| Leitzke ThomasSVP, Global Operations · 9 transactions | — | 139.8Kas of Aug 2013 | 135.0K | — | — |
| Tenney Maurice H.President-Brooks Life Sciences · 22 transactions | — | 136.6Kas of Feb 2019 | 329.6K | — | 141.0K |
| Robertson Lindon GEVP & Chief Financial Officer · 71 transactions | — | 121.1Kas of Nov 2023 | 589.7K | 24.4K | 413.8K |
| Mirchandani KushSVP, Worldwide Sales · 14 transactions | — | 120.8Kas of Dec 2013 | 65.0K | — | 7.4K |
| Joseph JasonSVP, General Counsel, Secy. · 108 transactions | — | 112.6Kas of Nov 2024 | 411.9K | — | 215.2K |
| Wrighton Mark SDirector · 18 transactions | — | 111.8Kas of Feb 2022 | 99.5K | — | — |
| Palepu Krishna G.Director · 19 transactions | — | 105.4Kas of Feb 2023 | 103.1K | 2.3K | — |
| Grady Edward CChief Executive Officer, Director · 9 transactions | — | 96.2Kas of Sep 2007 | 100.0K | — | 17.1K |
| Montone William T.SVP, Human Resources · 79 transactions | — | 91.9Kas of Sep 2021 | 327.2K | — | 268.5K |
| White SallySVP, Global Services · 3 transactions | — | 85.7Kas of Feb 2012 | 82.0K | — | — |
| Martin Joseph RDirector · 29 transactions | — | 85.2Kas of Jun 2023 | 143.7K | — | 52.2K |
| Allen A ClintonDirector · 53 transactions | — | 82.1Kas of Feb 2020 | 89.2K | 45.0K | — |
| Woollacott Alfred IIIDirector · 19 transactions | — | 81.7Kas of May 2019 | 104.1K | — | 14.4K |
| Lillig JohnSVP, MD, Brooks Life Sciences · 3 transactions | — | 81.5Kas of Jul 2012 | 80.0K | — | — |
| Lin Lawrence Y.EVP, CFO and Treasurer · 7 transactions | — | 79.7K | 73.7K | — | — |
| Woodbury Robert W JrExecutive VP & CFO · 9 transactions | — | 79.6Kas of Dec 2007 | 75.0K | — | — |
| Gray David CChief Strategy & New Business · 57 transactions | — | 74.9Kas of Nov 2023 | 322.6K | — | 185.9K |
| Wilson ShaunVP, Global Customer Operations · 5 transactions | — | 70.3Kas of Sep 2010 | 23.0K | — | 3.4K |
| Grilk Thomas SSr. VP, General Counsel · 27 transactions | — | 70.3Kas of Oct 2010 | 81.3K | — | 7.5K |
| Starr EphraimSVP, Gen Counsel & Secretary · 3 transactions | — | 68.4K | 72.0K | — | — |
| Mathews Timothy SPrincipal Accounting Officer · 19 transactions | — | 55.8Kas of May 2013 | 80.0K | — | 10.0K |
| Bellini JosephPresident & COO · 7 transactions | — | 53.0Kas of Mar 2007 | 51.8K | — | 51.8K |
| Pond Kirk PDirector · 7 transactions | — | 49.1Kas of Feb 2012 | 44.1K | 5.0K | — |
| Jarzynka DavidPresident, Semi Solutions · 36 transactions | — | 46.3Kas of Nov 2021 | 172.7K | — | 242.1K |
| Cornog William LDirector · 6 transactions | — | 45.5K | — | 29.5K | — |
| Zane Ellen MDirector · 13 transactions | — | 41.1Kas of Aug 2023 | 78.7K | — | — |
| Zhou GingerSVP and GM, Multiomics · 17 transactions | — | 38.8K | 37.1K | 417 | 1.6K |
| Anastasi Robert EExecutive Vice President · 11 transactions | — | 38.5Kas of Oct 2007 | 79.5K | — | 36.1K |
| Wuellner Ralf KPresident, Global Cust Op Grp · 5 transactions | — | 37.8Kas of Jun 2009 | 30.0K | — | 7.0K |
| Marvell GregoryVP, Extended Factory Group · 7 transactions | — | 36.8Kas of Feb 2011 | 15.0K | — | 40.1K |
| Park Chong SupDirector · 5 transactions | — | 36.6Kas of Dec 2012 | 36.6K | — | — |
| Small RichardSVP, Corporate Controller · 3 transactions | — | 36.1Kas of Dec 2007 | 10.0K | — | — |
| Davis Robyn CDirector · 10 transactions | — | 33.6Kas of Feb 2025 | 36.6K | — | 3.0K |
| Pirogova OlgaSVP and CHRO · 7 transactions | — | 33.0K | 36.2K | — | 1.6K |
| Vacha RobinSVP, GM Life Science Products · 24 transactions | — | 31.3Kas of Feb 2024 | 66.5K | — | 21.9K |
| McManus MatthewEVP & Chief Operating Officer · 1 transaction | — | 29.5Kas of Aug 2022 | — | 8.6K | — |
| Pietrantoni DavidPrincipal Accounting Officer · 64 transactions | — | 28.2Kas of Nov 2021 | 165.4K | — | 157.4K |
| Wang David DongSVP & GM, SMS · 6 transactions | — | 24.0Kas of Dec 2024 | 18.2K | — | 348 |
| Cueto HermanEVP, Chief Financial Officer · 5 transactions | — | 23.9Kas of Nov 2024 | 26.2K | — | 2.3K |
| McLaughlin EricaDirector · 7 transactions | — | 22.5K | 22.5K | — | — |
| Casal FrankDirector · 6 transactions | — | 21.8K | 21.8K | — | — |
| Pippins Michael WPresident, Automation Sys. Grp · 9 transactions | — | 20.4Kas of Jan 2009 | — | — | 11.6K |
| Gentilcore JamesPresident & COO · 16 transactions | — | 19.3Kas of Dec 2007 | 206.2K | — | 161.8K |
| Martin William E. IIIPresident Multiomics · 1 transaction | — | 17.8K | 17.8K | — | — |
| Malus Alan JDirector · 3 transactions | — | 17.0Kas of May 2025 | 4.0K | 12.0K | — |
| Nova Tina SusanDirector · 4 transactions | — | 15.8K | 15.8K | — | — |
| Emerick Roger DDirector · 1 transaction | — | 14.0Kas of Apr 2006 | — | — | 5.0K |
| Rosenblatt MichaelDirector · 9 transactions | — | 13.0Kas of Feb 2024 | 17.6K | — | 4.6K |
| Liao GuojuanPresident, GENEWIZ · 5 transactions | — | 12.8Kas of Nov 2020 | 15.1K | — | 2.3K |
| Doshi DipalDirector · 2 transactions | — | 9.7K | 9.7K | — | — |
| Hughes ViolettaVP, Chief Accounting Officer · 6 transactions | — | 9.6Kas of Feb 2025 | 8.6K | — | 480 |
| McGillicuddy John KDirector · 5 transactions | — | 9.5Kas of Nov 2015 | 20.0K | — | 10.5K |
| Madaus Martin DDirector · 2 transactions | — | 7.4Kas of Nov 2024 | 2.5K | 4.9K | — |
| Crowley KimberlySVP, Chief HR Officer · 7 transactions | — | 7.4Kas of Jan 2023 | 4.0K | — | 132 |
| Khoury Amin JDirector · 2 transactions | — | 7.2Kas of Apr 2006 | 7.2K | — | — |
| Sriram VandanaSVP Finance & Corp. Controller · 4 transactions | — | 6.4Kas of Jan 2023 | 3.2K | — | — |
| Puhy Dorothy EDirector · 1 transaction | — | 3.6Kas of Feb 2023 | 3.6K | — | — |
| Hirsch DidierDirector · 2 transactions | — | 3.5Kas of Nov 2024 | 2.5K | 1.0K | — |
| De Jesus LindaChief Commercial Officer, LS · 4 transactions | — | 2.8Kas of Jul 2022 | 1.6K | — | 191 |
| Bousa Edward PeterDirector · 1 transaction | — | 2.5Kas of Feb 2024 | 2.5K | — | — |
| Coyne MitchellSVP and GM, Life Sciences Proj · 1 transaction | — | 1.9Kas of Nov 2022 | 1.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -2.88M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.